{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T04:22:28Z","timestamp":1793161348707,"version":"4.5.0"},"reference-count":109,"publisher":"The Endocrine Society","issue":"10","funder":[{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["Z1AHD008735"],"award-info":[{"award-number":["Z1AHD008735"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021671","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021671","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002387","name":"NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002387","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Phe ochromocytomas and paragangliomas (PPGLs) are rare neural crest\u2013derived tumors with malignant potential and a highly variable natural history, where some patients achieve a cure through surgical resection, while others experience an aggressive and protracted disease course characterized by recurrence and metastasis. While currently no definitive curative treatment exists for metastatic PPGLs, ongoing trials and advances in biology of the disease present a beacon of hope. We present a case that illustrates a 15-year treatment journey, illustrating the complexity of metastatic PPGL treatment with different modalities, each with distinct efficacy and toxicity profiles. The choice of treatment is often an art, as much as it is based on evidence, as the clinician must balance among several factors, including tumor-related (pace of progression, tumor burden) and patient-related (functional status, symptoms, general health) ones. Through a stepwise approach, this discussion aims to provide insights into the evolving landscape of metastatic PPGL management.<\/jats:p>","DOI":"10.1210\/clinem\/dgaf259","type":"journal-article","created":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T08:15:41Z","timestamp":1746087341000},"page":"2946-2963","source":"Crossref","is-referenced-by-count":27,"title":["Approach to the Patient With Metastatic Pheochromocytoma and Paraganglioma"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0861-9348","authenticated-orcid":false,"given":"Hussam","family":"Alkaissi","sequence":"first","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-7600","authenticated-orcid":false,"given":"David","family":"Taieb","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Aix-Marseille University, La Timone University Hospital , 13005 Marseille ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank I","family":"Lin","sequence":"additional","affiliation":[{"name":"Molecular Imaging Branch, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9710-4030","authenticated-orcid":false,"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[{"name":"Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7795-1395","authenticated-orcid":false,"given":"Katharina","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine IV, University Hospital, Ludwig-Maximilians-University Munich , 80336 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1545-0368","authenticated-orcid":false,"given":"Roderick","family":"Clifton-Bligh","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Royal North Shore Hospital and Cancer Genetics Laboratory, Kolling Institute, University of Sydney , Sydney, New South Wales 2064 ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3541-3767","authenticated-orcid":false,"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"National Institutes of Health, Eunice Kennedy Shriver National Institute of Child Health and Human Development , Bethesda, MD 20892 ,","place":["USA"]},{"name":"Center for Adrenal Endocrine Tumors, AKESO , Prague 5 155 00 ,","place":["Czech Republic"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,5,3]]},"reference":[{"issue":"1","key":"2025091917012809900_dgaf259-B1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12022-022-09704-6","article-title":"Overview of the 2022 WHO classification of paragangliomas and pheochromocytomas","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"key":"2025091917012809900_dgaf259-B2","first-page":"16","article-title":"Das Ganglioma embryonale sympathicum (Sympathoma embryonale), eine typische b\u00f6sartige Geschwulstform des sympathischen Nervensystems","volume":"49","author":"Pick","year":"1912","journal-title":"Berlin Klin Wochenschr"},{"issue":"3","key":"2025091917012809900_dgaf259-B3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1677\/erc.1.00829","article-title":"Malignant pheochromocytoma: current status and initiatives for future progress","volume":"11","author":"Eisenhofer","year":"2004","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2025091917012809900_dgaf259-B4","doi-asserted-by":"crossref","first-page":"101958","DOI":"10.1016\/j.beem.2024.101958","article-title":"Recent progress in the pathologic classification of pheochromocytomas and paragangliomas","volume":"38","author":"Mete","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2025091917012809900_dgaf259-B5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1158\/1078-0432.CCR-18-0139","article-title":"Telomerase activation and ATRX mutations are independent risk factors for metastatic pheochromocytoma and paraganglioma","volume":"25","author":"Job","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025091917012809900_dgaf259-B6","doi-asserted-by":"crossref","first-page":"6140","DOI":"10.1038\/ncomms7140","article-title":"Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas","volume":"6","author":"Fishbein","year":"2015","journal-title":"Nat Commun"},{"key":"2025091917012809900_dgaf259-B7","doi-asserted-by":"crossref","first-page":"1399847","DOI":"10.3389\/fendo.2024.1399847","article-title":"Case series: ATRX variants in four patients with metastatic pheochromocytoma","volume":"15","author":"Cortez","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"14","key":"2025091917012809900_dgaf259-B8","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1158\/1078-0432.CCR-17-3406","article-title":"Targeting NAD\/PARP DNA repair pathway as a novel therapeutic approach to -mutated cluster I pheochromocytoma and paraganglioma","volume":"24","author":"Pang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2025091917012809900_dgaf259-B9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother Oncol"},{"issue":"12","key":"2025091917012809900_dgaf259-B10","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.eprac.2022.09.003","article-title":"New biology of pheochromocytoma and paraganglioma","volume":"28","author":"Pacak","year":"2022","journal-title":"Endocr Pract"},{"issue":"4","key":"2025091917012809900_dgaf259-B11","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/ERC-21-0359","article-title":"Head\/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine","volume":"29","author":"Richter","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2025091917012809900_dgaf259-B12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejca.2022.03.032","article-title":"Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma","volume":"169","author":"Pamporaki","year":"2022","journal-title":"Eur J Cancer"},{"issue":"11","key":"2025091917012809900_dgaf259-B13","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1016\/j.ejca.2011.07.016","article-title":"Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status","volume":"48","author":"Eisenhofer","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"2025091917012809900_dgaf259-B14","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1186\/1471-2407-14-523","article-title":"The size of the primary tumor and age at initial diagnosis are independent predictors of the metastatic behavior and survival of patients with SDHB-related pheochromocytoma and paraganglioma: a retrospective cohort study","volume":"14","author":"Schovanek","year":"2014","journal-title":"BMC Cancer"},{"issue":"6","key":"2025091917012809900_dgaf259-B15","doi-asserted-by":"crossref","first-page":"e1985","DOI":"10.1210\/clinem\/dgae612","article-title":"Presentation, management, and outcomes of patients with giant pheochromocytoma: retrospective cohort study","volume":"110","author":"Bahrani Fard","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025091917012809900_dgaf259-B16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","article-title":"Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: an international expert consensus statement","volume":"20","author":"Taieb","year":"2024","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2025091917012809900_dgaf259-B17","doi-asserted-by":"crossref","first-page":"302","DOI":"10.4158\/EP15725.OR","article-title":"Characteristics and outcomes of metastatic Sdhb and sporadic pheochromocytoma\/paraganglioma: an national institutes of health study","volume":"22","author":"Turkova","year":"2016","journal-title":"Endocr Pract"},{"issue":"5","key":"2025091917012809900_dgaf259-B18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1530\/ERC-19-0024","article-title":"Genotype-phenotype correlations in pheochromocytoma and paraganglioma: a systematic review and individual patient meta-analysis","volume":"26","author":"Crona","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2025091917012809900_dgaf259-B19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41467-023-36769-6","article-title":"Genomic and immune landscape of metastatic pheochromocytoma and paraganglioma","volume":"14","author":"Calsina","year":"2023","journal-title":"Nat Commun"},{"issue":"12","key":"2025091917012809900_dgaf259-B20","doi-asserted-by":"crossref","first-page":"e4661","DOI":"10.1210\/clinem\/dgaa608","article-title":"Predicting metastatic potential in pheochromocytoma and paraganglioma: a comparison of PASS and GAPP scoring systems","volume":"105","author":"Wachtel","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025091917012809900_dgaf259-B21","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/00000478-200205000-00002","article-title":"Pheochromocytoma of the adrenal gland scaled score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases","volume":"26","author":"Thompson","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"2025091917012809900_dgaf259-B22","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1530\/ERC-13-0494","article-title":"Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma","volume":"21","author":"Kimura","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2025091917012809900_dgaf259-B23","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00428-019-02553-5","article-title":"COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas\/paragangliomas","volume":"474","author":"Pierre","year":"2019","journal-title":"Virchows Arch"},{"issue":"2","key":"2025091917012809900_dgaf259-B24","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2017.01.001","article-title":"Comprehensive molecular characterization of pheochromocytoma and paraganglioma","volume":"31","author":"Fishbein","year":"2017","journal-title":"Cancer Cell"},{"issue":"4","key":"2025091917012809900_dgaf259-B25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1210\/endrev\/bnae005","article-title":"The immune landscape of pheochromocytoma and paraganglioma: current advances and perspectives","volume":"45","author":"Uher","year":"2024","journal-title":"Endocr Rev"},{"issue":"11","key":"2025091917012809900_dgaf259-B26","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-20-0205","article-title":"HIF2alpha supports pro-metastatic behavior in pheochromocytomas\/paragangliomas","volume":"27","author":"Bechmann","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2025091917012809900_dgaf259-B27","doi-asserted-by":"crossref","first-page":"101931","DOI":"10.1016\/j.beem.2024.101931","article-title":"MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma","volume":"38","author":"Monteagudo","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2025091917012809900_dgaf259-B28","doi-asserted-by":"crossref","first-page":"6262","DOI":"10.1038\/s41467-022-34011-3","article-title":"Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment","volume":"13","author":"Zethoven","year":"2022","journal-title":"Nat Commun"},{"key":"2025091917012809900_dgaf259-B29","doi-asserted-by":"crossref","first-page":"1045517","DOI":"10.3389\/fonc.2022.1045517","article-title":"PD-L1 expression and association with genetic background in pheochromocytoma and paraganglioma","volume":"12","author":"Hadrava Vanova","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"2025091917012809900_dgaf259-B30","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12020-022-03218-1","article-title":"Immune signature of pheochromocytoma and paraganglioma in context of neuroendocrine neoplasms associated with prognosis","volume":"79","author":"Ghosal","year":"2023","journal-title":"Endocrine"},{"issue":"1","key":"2025091917012809900_dgaf259-B31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-17-0306","article-title":"TERT structural rearrangements in metastatic pheochromocytomas","volume":"25","author":"Dwight","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2025091917012809900_dgaf259-B32","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1038\/s41467-022-33099-x","article-title":"Conserved features of TERT promoter duplications reveal an activation mechanism that mimics hotspot mutations in cancer","volume":"13","author":"Barger","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"2025091917012809900_dgaf259-B33","first-page":"2632","article-title":"Multi-omic analysis of SDHB-deficient pheochromocytomas and paragangliomas identifies metastasis and treatment-related molecular profiles","volume":"16","author":"Flynn","year":"2025","journal-title":"Res Sq"},{"issue":"9","key":"2025091917012809900_dgaf259-B34","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2589-7500(23)00094-8","article-title":"Prediction of metastatic pheochromocytoma and paraganglioma: a machine learning modelling study using data from a cross-sectional cohort","volume":"5","author":"Pamporaki","year":"2023","journal-title":"Lancet Digit Health"},{"issue":"2","key":"2025091917012809900_dgaf259-B35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3390\/metabo7020017","article-title":"Mitochondrial deficiencies in the predisposition to paraganglioma","volume":"7","author":"Lussey-Lepoutre","year":"2017","journal-title":"Metabolites"},{"issue":"8","key":"2025091917012809900_dgaf259-B36","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.bbabio.2014.03.013","article-title":"Unsuspected task for an old team: succinate, fumarate and other Krebs cycle acids in metabolic remodeling","volume":"1837","author":"Benit","year":"2014","journal-title":"Biochim Biophys Acta"},{"issue":"5","key":"2025091917012809900_dgaf259-B37","doi-asserted-by":"crossref","first-page":"L21","DOI":"10.1530\/EJE-21-0258","article-title":"Incidence of pheochromocytoma and paraganglioma varies according to altitude: meta-regression analysis","volume":"184","author":"Leung","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025091917012809900_dgaf259-B38","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-14-0113","article-title":"Therapy of endocrine disease: treatment of malignant pheochromocytoma and paraganglioma","volume":"171","author":"Baudin","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025091917012809900_dgaf259-B39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/MED.0000000000000330","article-title":"Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials","volume":"24","author":"Roman-Gonzalez","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"2025091917012809900_dgaf259-B40","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1210\/clinem\/dgac563","article-title":"Recurrent disease in patients with sporadic pheochromocytoma and paraganglioma","volume":"108","author":"Li","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"10431","key":"2025091917012809900_dgaf259-B41","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/S0140-6736(23)02554-0","article-title":"Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial","volume":"403","author":"Baudin","year":"2024","journal-title":"Lancet"},{"issue":"4","key":"2025091917012809900_dgaf259-B42","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1210\/jc.2012-4231","article-title":"Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma","volume":"98","author":"Ayala-Ramirez","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025091917012809900_dgaf259-B43","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1210\/jc.2017-00992","article-title":"Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years","volume":"102","author":"Hamidi","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2025091917012809900_dgaf259-B44","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S2213-8587(23)00256-5","article-title":"Catecholamine-induced hypertensive crises: current insights and management","volume":"11","author":"Nazari","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2025091917012809900_dgaf259-B45","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1210\/clinem\/dgae252","article-title":"Approach to the patient: concept and application of targeted radiotherapy in the paraganglioma patient","volume":"109","author":"Pacak","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2025091917012809900_dgaf259-B46","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers11070909","article-title":"Favorable outcome in patients with pheochromocytoma and paraganglioma treated with lu-DOTATATE","volume":"11","author":"Vyakaranam","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2025091917012809900_dgaf259-B47","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jnci\/djs188","article-title":"Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography","volume":"104","author":"Timmers","year":"2012","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"2025091917012809900_dgaf259-B48","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","article-title":"Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension","volume":"38","author":"Lenders","year":"2020","journal-title":"J Hypertens"},{"issue":"10","key":"2025091917012809900_dgaf259-B49","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1007\/s00259-019-04398-1","article-title":"European association of nuclear medicine practice guideline\/society of nuclear medicine and molecular imaging procedure standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma","volume":"46","author":"Taieb","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"2025091917012809900_dgaf259-B50","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1007\/s00259-023-06261-w","article-title":"Molecular imaging phenotyping of germline fumarate hydratase (FH) pathogenic variant-positive metastatic pheochromocytoma","volume":"50","author":"Imperiale","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"2025091917012809900_dgaf259-B51","first-page":"e176","article-title":"Functional imaging experience in a germline fumarate hydratase mutation\u2013positive patient with pheochromocytoma and paraganglioma","volume":"2","author":"Nambuba","year":"2016","journal-title":"AACE Clin Case Rep"},{"issue":"5","key":"2025091917012809900_dgaf259-B52","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S2213-8587(23)00038-4","article-title":"Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants","volume":"11","author":"Taieb","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"2025091917012809900_dgaf259-B53","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1245\/s10434-008-9977-z","article-title":"Surgical management of carotid body tumors","volume":"15","author":"Makeieff","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2025091917012809900_dgaf259-B54","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1002\/ijc.28913","article-title":"SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma","volume":"135","author":"Hadoux","year":"2014","journal-title":"Int J Cancer"},{"issue":"3","key":"2025091917012809900_dgaf259-B55","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.1210\/clinem\/dgae283","article-title":"Clinical activity of selpercatinib in RET-mutant pheochromocytoma","volume":"110","author":"Deschler-Baier","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"22","key":"2025091917012809900_dgaf259-B56","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa2110051","article-title":"Belzutifan, a potent HIF2alpha inhibitor, in the Pacak-Zhuang syndrome","volume":"385","author":"Kamihara","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"2025091917012809900_dgaf259-B57","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1038\/s41588-018-0170-4","article-title":"Krebs-cycle-deficient hereditary cancer syndromes are defined by defects in homologous-recombination DNA repair","volume":"50","author":"Sulkowski","year":"2018","journal-title":"Nat Genet"},{"issue":"12","key":"2025091917012809900_dgaf259-B58","doi-asserted-by":"crossref","first-page":"e4980","DOI":"10.1210\/clinem\/dgaa602","article-title":"Response to Letter to the Editor: \u201cApproach to the patient: perioperative management of the patient with pheochromocytoma or sympathetic paraganglioma\u201d","volume":"105","author":"Berends","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2025091917012809900_dgaf259-B59","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMc2409427","article-title":"Rapid cardiovascular response to Belzutifan in HIF2A-mediated paraganglioma","volume":"391","author":"Alkaissi","year":"2024","journal-title":"N Engl J Med"},{"key":"2025091917012809900_dgaf259-B60","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.humpath.2018.11.020","article-title":"Variable somatostatin receptor subtype expression in 151 primary pheochromocytomas and paragangliomas","volume":"86","author":"Leijon","year":"2019","journal-title":"Hum Pathol"},{"issue":"2","key":"2025091917012809900_dgaf259-B61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/107327481101800205","article-title":"Changing paradigms in the treatment of malignant pheochromocytoma","volume":"18","author":"Grogan","year":"2011","journal-title":"Cancer Control"},{"issue":"3_pt_2","key":"2025091917012809900_dgaf259-B62","doi-asserted-by":"crossref","first-page":"I18","DOI":"10.1161\/01.HYP.7.3_Pt_2.I18","article-title":"Treatment of malignant pheochromocytoma with combination chemotherapy","volume":"7","author":"Keiser","year":"1985","journal-title":"Hypertension"},{"issue":"4","key":"2025091917012809900_dgaf259-B63","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"issue":"8","key":"2025091917012809900_dgaf259-B64","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1002\/cncr.23812","article-title":"Treatment of malignant pheochromocytoma\/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients","volume":"113","author":"Huang","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"2025091917012809900_dgaf259-B65","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12672-013-0133-2","article-title":"Combination chemotherapy with cyclophosphamide, vincristine, and dacarbazine in patients with malignant pheochromocytoma and paraganglioma","volume":"4","author":"Tanabe","year":"2013","journal-title":"Horm Cancer"},{"issue":"2","key":"2025091917012809900_dgaf259-B66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12020-009-9219-6","article-title":"Successful chemotherapy of hepatic metastases in a case of succinate dehydrogenase subunit B-related paraganglioma","volume":"36","author":"He","year":"2009","journal-title":"Endocrine"},{"issue":"7","key":"2025091917012809900_dgaf259-B67","first-page":"1093","article-title":"Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer","volume":"3","author":"Dhodapkar","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025091917012809900_dgaf259-B68","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1200\/JCO.2000.18.1.158","article-title":"Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma","volume":"18","author":"Middleton","year":"2000","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025091917012809900_dgaf259-B69","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"2025091917012809900_dgaf259-B70","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2025091917012809900_dgaf259-B71","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1055\/s-0029-1224135","article-title":"Clinical utility of temozolomide in the treatment of malignant paraganglioma: a preliminary report","volume":"41","author":"Bravo","year":"2009","journal-title":"Horm Metab Res"},{"issue":"6","key":"2025091917012809900_dgaf259-B72","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1158\/1078-0432.CCR-20-3788","article-title":"Integrated molecular characterization of fumarate hydratase-deficient renal cell carcinoma","volume":"27","author":"Sun","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"7","key":"2025091917012809900_dgaf259-B73","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","article-title":"Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands","volume":"28","author":"Reubi","year":"2001","journal-title":"Eur J Nucl Med"},{"issue":"11","key":"2025091917012809900_dgaf259-B74","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1210\/jc.2003-030262","article-title":"Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy","volume":"88","author":"Mundschenk","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2025091917012809900_dgaf259-B75","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.2967\/jnumed.110.075226","article-title":"Phase I trial of 90Y\u2013DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptors","volume":"51","author":"Menda","year":"2010","journal-title":"J Nucl Med"},{"issue":"5","key":"2025091917012809900_dgaf259-B76","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2967\/jnumed.118.217463","article-title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma","volume":"60","author":"Pryma","year":"2019","journal-title":"J Nucl Med"},{"issue":"12","key":"2025091917012809900_dgaf259-B77","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","article-title":"(177)Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Strosberg","year":"2021","journal-title":"Lancet Oncol"},{"issue":"17","key":"2025091917012809900_dgaf259-B78","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/1078-0432.CCR-14-2751","article-title":"Superiority of [68Ga]-DOTATATE PET\/CT to other functional imaging modalities in the localization of SDHB-associated metastatic pheochromocytoma and paraganglioma","volume":"21","author":"Janssen","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2025091917012809900_dgaf259-B79","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40644-016-0084-2","article-title":"(68)Ga-DOTATATE and (18)F-FDG PET\/CT in paraganglioma and pheochromocytoma: utility, patterns and heterogeneity","volume":"16","author":"Chang","year":"2016","journal-title":"Cancer Imaging"},{"issue":"3","key":"2025091917012809900_dgaf259-B80","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s12020-024-03915-z","article-title":"Hematological toxicities with Lutathera(R) for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA","volume":"86","author":"Grewal","year":"2024","journal-title":"Endocrine"},{"issue":"5","key":"2025091917012809900_dgaf259-B81","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ejendo\/lvad146","article-title":"Responses to systemic therapy in metastatic pheochromocytoma\/paraganglioma: a retrospective multicenter cohort study","volume":"189","author":"Fischer","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2025091917012809900_dgaf259-B82","doi-asserted-by":"crossref","first-page":"R239","DOI":"10.1530\/ERC-20-0043","article-title":"Antiangiogenic therapies for pheochromocytoma and paraganglioma","volume":"27","author":"Jimenez","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"2025091917012809900_dgaf259-B83","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","article-title":"A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial","volume":"120","author":"O'Kane","year":"2019","journal-title":"Br J Cancer"},{"key":"2025091917012809900_dgaf259-B84","doi-asserted-by":"crossref","first-page":"114276","DOI":"10.1016\/j.ejca.2024.114276","article-title":"Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: the phase 2 non-randomized SUTNET clinical trial","volume":"209","author":"Nasca","year":"2024","journal-title":"Eur J Cancer"},{"issue":"5","key":"2025091917012809900_dgaf259-B85","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/S1470-2045(24)00133-5","article-title":"Cabozantinib in patients with unresectable and progressive metastatic phaeochromocytoma or paraganglioma (the Natalie trial): a single-arm, phase 2 trial","volume":"25","author":"Jimenez","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"2025091917012809900_dgaf259-B86","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-017-1359-5","article-title":"Phase II trial of pazopanib in advanced\/progressive malignant pheochromocytoma and paraganglioma","volume":"57","author":"Jasim","year":"2017","journal-title":"Endocrine"},{"issue":"5","key":"2025091917012809900_dgaf259-B87","doi-asserted-by":"crossref","first-page":"bvac044","DOI":"10.1210\/jendso\/bvac044","article-title":"Lenvatinib as a therapeutic option in unresectable metastatic pheochromocytoma and paragangliomas","volume":"6","author":"Hassan Nelson","year":"2022","journal-title":"J Endocr Soc"},{"issue":"16_suppl","key":"2025091917012809900_dgaf259-B88","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2024.42.16_suppl.4602","article-title":"Single agent axitinib in the management of patients with progressive pheochromocytoma and paraganglioma","volume":"42","author":"Fojo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"2025091917012809900_dgaf259-B89","doi-asserted-by":"crossref","first-page":"bvae061","DOI":"10.1210\/jendso\/bvae061","article-title":"Anlotinib for metastatic progressed pheochromocytoma and paraganglioma: a retrospective study of real-world data","volume":"8","author":"Tian","year":"2024","journal-title":"J Endocr Soc"},{"issue":"7","key":"2025091917012809900_dgaf259-B90","doi-asserted-by":"crossref","first-page":"bvae092","DOI":"10.1210\/jendso\/bvae092","article-title":"A targetable receptor tyrosine kinase in metastatic pheochromocytoma and paraganglioma: a future journey for anlotinib?","volume":"8","author":"Alkaissi","year":"2024","journal-title":"J Endocr Soc"},{"issue":"4","key":"2025091917012809900_dgaf259-B91","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/MPA.0000000000001792","article-title":"The North American neuroendocrine tumor society consensus guidelines for surveillance and management of metastatic and\/or unresectable pheochromocytoma and paraganglioma","volume":"50","author":"Fishbein","year":"2021","journal-title":"Pancreas"},{"issue":"7","key":"2025091917012809900_dgaf259-B92","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41574-021-00492-3","article-title":"International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers","volume":"17","author":"Amar","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2025091917012809900_dgaf259-B93","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1210\/jc.2018-02411","article-title":"Positive impact of genetic test on the management and outcome of patients with paraganglioma and\/or pheochromocytoma","volume":"104","author":"Buffet","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2025091917012809900_dgaf259-B94","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1210\/clinem\/dgae233","article-title":"Outcomes of SDHB pathogenic variant carriers","volume":"109","author":"Davidoff","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025091917012809900_dgaf259-B95","doi-asserted-by":"crossref","first-page":"e1907","DOI":"10.1210\/clinem\/dgac019","article-title":"Surveillance improves outcomes for carriers of SDHB pathogenic variants: a multicenter study","volume":"107","author":"Davidoff","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025091917012809900_dgaf259-B96","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.surg.2018.05.001","article-title":"A clinical prediction model to estimate the metastatic potential of pheochromocytoma\/paraganglioma: ASES score","volume":"164","author":"Cho","year":"2018","journal-title":"Surgery"},{"issue":"9","key":"2025091917012809900_dgaf259-B97","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1093\/hmg\/ddt639","article-title":"Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas","volume":"23","author":"Castro-Vega","year":"2014","journal-title":"Hum Mol Genet"},{"issue":"4","key":"2025091917012809900_dgaf259-B98","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/ng849","article-title":"Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer","volume":"30","author":"Tomlinson","year":"2002","journal-title":"Nat Genet"},{"issue":"2","key":"2025091917012809900_dgaf259-B99","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1210\/endrev\/bnab019","article-title":"Personalized management of pheochromocytoma and paraganglioma","volume":"43","author":"Nolting","year":"2022","journal-title":"Endocr Rev"},{"key":"2025091917012809900_dgaf259-B100","doi-asserted-by":"crossref","first-page":"217464","DOI":"10.1016\/j.canlet.2025.217464","article-title":"Neoadjuvant intratumoral MBT(A) immunotherapy prevents distant metastases and recurrence in murine models","volume":"612","author":"Uher","year":"2025","journal-title":"Cancer Lett"},{"issue":"1","key":"2025091917012809900_dgaf259-B101","doi-asserted-by":"crossref","first-page":"101941","DOI":"10.1016\/j.beem.2024.101941","article-title":"Role of B cells in intratumoral MBTA immunotherapy of murine pheochromocytoma model","volume":"39","author":"Uher","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"2025091917012809900_dgaf259-B102","doi-asserted-by":"crossref","first-page":"101913","DOI":"10.1016\/j.beem.2024.101913","article-title":"Pre-clinical phaeochromocytoma and paraganglioma models: cell lines, animal models, and a human primary culture model","volume":"38","author":"Wang","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"2025091917012809900_dgaf259-B103","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1210\/en.2019-00410","article-title":"Synergistic highly potent targeted drug combinations in different pheochromocytoma models including human tumor cultures","volume":"160","author":"Fankhauser","year":"2019","journal-title":"Endocrinology"},{"issue":"6","key":"2025091917012809900_dgaf259-B104","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1530\/ERC-21-0355","article-title":"Personalized drug testing in human pheochromocytoma\/paraganglioma primary cultures","volume":"29","author":"Wang","year":"2022","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"2025091917012809900_dgaf259-B105","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/clinem\/dgae241","article-title":"Opposing effects of cannabidiol in patient-derived neuroendocrine tumor, pheochromocytoma\/paraganglioma primary cultures","volume":"109","author":"Wang","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025091917012809900_dgaf259-B106","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ejendo\/lvae163","article-title":"Impact of sex hormones on pheochromocytomas, paragangliomas, and gastroenteropancreatic neuroendocrine tumors","volume":"192","author":"Wang","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025091917012809900_dgaf259-B107","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1007\/s00259-019-04567-2","article-title":"Broadening horizons with (225)Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to (177)Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety","volume":"47","author":"Ballal","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"2025091917012809900_dgaf259-B108","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2967\/jnumed.121.263230","article-title":"Targeted \u03b1-emitter therapy with (212)Pb-DOTAMTATE for the treatment of metastatic SSTR-expressing neuroendocrine tumors: first-in-humans dose-escalation clinical trial","volume":"63","author":"Delpassand","year":"2022","journal-title":"J Nucl Med"},{"issue":"5","key":"2025091917012809900_dgaf259-B109","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1210\/jc.2017-01991","article-title":"Pheochromocytoma\/paraganglioma: a poster child for cancer metabolism","volume":"103","author":"Tevosian","year":"2018","journal-title":"J Clin Endocrinol Metab"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaf259\/63049932\/dgaf259.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/10\/2946\/63049932\/dgaf259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/10\/2946\/63049932\/dgaf259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T21:01:45Z","timestamp":1758315705000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/10\/2946\/8124472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":109,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,5,3]]},"published-print":{"date-parts":[[2025,9,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaf259","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,5,3]]}}}